Carasent AB (publ) CARA.ST
Nasdaq Stockholm · Healthcare · Health Information Services
25.60 SEK
−1.0%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Carasent
| SEK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 208 | 245 | 275 | 344 |
| EBITDA | 74 | 3 | 18 | 96 |
| Net income | 33 | −47 | −42 | 35 |
| Balance sheet | ||||
| Equity | 1,298 | 943 | 893 | 808 |
| Total debt | 39 | 50 | 41 | 32 |
| Cash | 737 | 367 | 262 | 138 |
| Net debt | −698 | −317 | −221 | −106 |
| Ratios and per share | ||||
| EBITDA margin | 35.5% | 1.2% | 6.4% | 28.1% |
| Profit margin | 16.0% | −19.0% | −15.4% | 10.1% |
| Return on equity | 2.6% | −4.9% | −4.7% | 4.3% |
| Earnings/share (SEK) | 0.42 | −0.65 | −0.58 | 0.51 |
| Book value/share (SEK) | 16.30 | 13.04 | 12.35 | 11.80 |
| Shares outstanding (M) | 80 | 72 | 72 | 68 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 50.6 |
| P/B | 2.2 |
| EV / EBITDA | 17.1 |
| Net debt / EBITDA | −1.1 |
| Return on equity | 4.3% |
| Profit margin | 10.1% |
| Beta 1Y | 0.56 |
| Revenue growth 1Y | +24.9% |
| Revenue CAGR 3Y | +18.3% |
| Earnings/share CAGR 3Y | +6.7% |
| ROE avg. 3Y | −1.8% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (SEK)
| 2023 | 1.92 |
Not investment advice. Figures may contain errors from the data source.